Financial Performance - In 2015, the company achieved total operating revenue of ¥712,738,059.09, a decrease of 11.01% compared to the previous year[3] - Operating profit for 2015 was ¥220,628,307.40, reflecting an increase of 28.22% year-on-year[4] - The net profit attributable to shareholders was ¥197,401,922.59, representing a year-on-year growth of 33.38%[4] - Basic earnings per share increased to ¥0.25, up 31.58% from ¥0.19 in the previous year[3] - The weighted average return on equity rose to 7.94%, an increase of 1.82 percentage points[3] - The company's equity attributable to shareholders increased slightly by 0.47% to ¥2,469,228,813.85[3] Assets and Structure - Total assets at the end of the reporting period were ¥2,681,630,814.62, a decrease of 1.21% from the beginning of the period[3] - The company reported a change in product sales structure with an increase in self-developed products and a decrease in agency products[5] - The company launched a new self-developed product, the AC-Hib combination vaccine, contributing to changes in the sales structure[5] Corporate Governance - The company emphasizes the importance of accurate information disclosure and investor risk awareness[2]
智飞生物(300122) - 2015 Q4 - 年度业绩